ArticlePloS one2014
Analysis of cross-reactive neutralizing antibodies in human HFMD serum with an EV71 pseudovirus-based assay.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01636245 (Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71), which is not on this map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Immunogenicity and Safety of Three Consecutive Lots of a New Inactivated Enterovirus Type 71 (EV71) Vaccine: A Double-blind, Randomized and Controlled Trial
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- Emergence of genotype C1 Enterovirus A71 and its link with antigenic variation of virus in Taiwan.PLoS pathogens · 2020Trial
- Immunity and clinical efficacy of an inactivated enterovirus 71 vaccine in healthy Chinese children: a report of further observations.BMC medicine · 2015Trial
- Article
- Antisera-Neutralizing Capacity of a Highly Evolved Type 2 Vaccine-Derived Poliovirus from an Immunodeficient Patient.Viruses · 2024Article
- Pseudotyped Viruses for Enterovirus.Advances in experimental medicine and biology · 2023Article
- Application of Pseudotyped Viruses.Advances in experimental medicine and biology · 2023Review
- Evaluation of the cross-neutralization activities elicited by Coxsackievirus A10 vaccine strains.Human vaccines & immunotherapeutics · 2021Article
- The epidemiological characteristics of enterovirus infection before and after the use of enterovirus 71 inactivated vaccine in Kunming, China.Emerging microbes & infections · 2021Article
- Insights into innate and adaptive immune responses in vaccine development against EV-A71.Therapeutic advances in vaccines and immunotherapy · 2019Review
- Seroprevalence of antibodies to enterovirus 71 and coxsackievirus A16 among people of various age groups in a northeast province of Thailand.Virology journal · 2018Article
- Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Review
- T Cell Immunity To Enterovirus 71 Infection In Humans And Implications For Vaccine Development.International journal of medical sciences · 2018Review
- Immunopathogenesis and Virus-Host Interactions of Enterovirus 71 in Patients with Hand, Foot and Mouth Disease.Frontiers in microbiology · 2017Review
- Epidemiological and genetic characteristics of EV71 in hand, foot, and mouth disease in Guangxi, southern China, from 2010 to 2015.PloS one · 2017Article
- Prediction of Protection against Asian Enterovirus 71 Outbreak Strains by Cross-neutralizing Capacity of Serum from Dutch Donors, The Netherlands.Emerging infectious diseases · 2016Article
- Hand, Foot, and Mouth Disease in China: Modeling Epidemic Dynamics of Enterovirus Serotypes and Implications for Vaccination.PLoS medicine · 2016Article
- Development of Novel Vaccines against Enterovirus-71.Viruses · 2015Review
- Phylodynamics of Enterovirus A71-Associated Hand, Foot, and Mouth Disease in Viet Nam.Journal of virology · 2015Article
- Article
- Immunogenicity and protective efficacy of an EV71 virus-like particle vaccine against lethal challenge in newborn mice.Human vaccines & immunotherapeutics · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hand, foot and mouth disease, associated with enterovirus 71 (EV71) infections, has recently become an important public health issue throughout the world. Serum neutralizing antibodies are major indicators of EV71 infection and protective immunity. However, the potential for cross-reactivity of neutralizing antibodies for different EV71 genotypes and subgenotypes is unclear. Here we measured the cross-reactive neutralizing antibody titers against EV71 of different genotypes or subgenotypes in sera collected from EV71-infected children and vaccine-inoculated children in a phase III clinical trial (ClinicalTrials.gov Identifier: NCT01636245) using a new pseudovirus-based neutralization assay. Antibodies induced by EV71-C4a were cross-reactive for different EV71 genotypes, demonstrating that C4a is a good candidate strain for an EV71 vaccine. Our study also demonstrated that this new assay is practical for analyses of clinical samples from epidemiological and vaccine studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.